strong guid increas solid outlook
put anoth impress revenu growth quarter revenu
come street beat despit head wind
point ww growth quarter move pharmaci channel price
overal channel basi stabl slightli think near-
term price willingli give move pharmaci channel make lot
strateg sens higher mix pharmaci channel like accret
revenu growth start late new patient higher util also
accret profit margin set seem solid view new
patient referr come faster rate ever new patient pipelin doubl
medicar continu build nice intern busi essenti
doubl everi singl major market ou growth y/i
q/q wait januari provid offici guidanc manag
say comfort current street estim low growth
given momentum busi growth could ultim prove
conserv view upcom dec analyst day also like posit
near-term catalyst reiter buy rate
rel new cfo start show sign turn corner
profit without sacrif invest new growth opportun
gener record op profit sg q/q
despit q/q increas revenu year date grown opex less
half rate revenu like lay long term profit target
time could see gener low ebitda margin
also take advantag new pathway two new product approv come
record time clinic trial need comment
begin also bullish view dxcm recent new fully-
dispos indic patient even without diabet softwar applic
peopl non-intens diabet new product like
use new market test rather full scale product minim revenu
could still acceler dxcm effort move new market opportun beyond
type diabet even diabet shift signific resourc second-
gener verili devic expect late earli
net dbt
sign momentum slow
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
dexcom inc oper medic devic
compani focus design develop
continu glucos monitor cgm system
peopl diabet compani
develop small implant devic
continu measur glucos level
subcutan tissu skin real-tim
data process display patient
also alert level high low
product market physician
endocrinologist diabet educ
see sever avenu beat street
estim launch medicar
conserv assumpt util price
competit could drive upsid near term
long-term penetr non-intens type
increas total avail market opportun
also beleiv cgm remain top-tier
growth market patient adopt cgm
beneficiari tailwind
rais estim higher revenu progress profit
valu ev/sal given compani unprofit today price
object base revenu estim multipl line
small mid-cap med-tech compani similar revenu growth rate
upsid risk strateg activ launch medicar ad patient
expect less impact expect competit faster approv
pipelin product downsid risk price pressur fewer patient
added/high attrit current patient due competitor threat lack patient
want adopt cgm delay pipelin product
travi steed herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
